Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

67.01 +0.43 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
61 62 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion
CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments 
Via Spotlight Growth
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal
AstraZeneca stock wavered as it agreed to buy CinCor Pharma, maker of blood pressure drug baxdrostat for $1.8 billion. CINC stock soared. 
Via Investor's Business Daily
Why Shares of Compugen Rose on Thursday
The clinical-stage biotech retreated a bit from one of its biggest days in a while. 
Via The Motley Fool
This Favorable Sign Appears On AstraZeneca's Chart
Via Benzinga
Why Is CinCor (CINC) Stock Up 138% Today?
CinCor (CINC) stock is rocketing higher on Monday following news that AstraZeneca (AZN) is acquiring the company for up to $1.8 billion. 
Via InvestorPlace
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Bloomberg 
Via Benzinga
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
1 Stock Defying the Downturn to Buy, and 1 to Avoid
These two stocks might go in different directions in the future. 
Via The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
Via Benzinga
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
From Tempus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
AstraZeneca Stock Scores Relative Strength Rating Upgrade
AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
What Does AstraZeneca's Debt Look Like?
Shares of AstraZeneca Inc. (NASDAQ:AZN) moved higher by 28.78% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies look poised to continue their runs. 
Via The Motley Fool
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study
Via Benzinga
Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang
You don't need a mountain of money to grow your wealth on Wall Street. 
Via The Motley Fool
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
Healthcare is a sector that has proven to be reliable in recessions. 
Via The Motley Fool
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
Via Benzinga
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Could AstraZeneca's Asthma Drug Candidate Generate Billions?
AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults. 
Via The Motley Fool
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Via Benzinga
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting
Via Benzinga
Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results
Guardant spent more money than it took in while hoping to become a leader in cancer diagnosis, but accuracy remains a problem. 
Via InvestorPlace
2 Best Biotech Stocks to Buy Right Now
Demand for medicines and vaccines has nowhere to go but up over the long run. 
Via The Motley Fool
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.